Evidence map›Paper›PMID 30180214›Full record

ArticlePLoS pathogens2018

HLA-C downregulation by HIV-1 adapts to host HLA genotype.

Nathaniel D Bachtel, Gisele Umviligihozo, Suzanne Pickering, Talia M Mota, Hua Liang, Gregory Q Del Prete, Pramita Chatterjee, Guinevere Q Lee, Rasmi Thomas, Mark A Brockman and 14 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. MHC Class I Ligands of Rhesus Macaque Killer Cell Ig-like Receptors.Journal of immunology (Baltimore, Md. : 1950) · 2023
    Article
  7. Article
  8. Review
  9. Article
  10. Frontiers in immunology · 2022
    Article
  11. Review
  12. Article
  13. An immunogenetic view of COVID-19.Genetics and molecular biology · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 11 institutions in 5 countries.

Nathaniel D BachtelDepartment of Microbiology, Immunology & Tropical Medicine, The George Washington University, Washington DC, United States of America.ORCID 0000-0002-2631-2243
Gisele UmviligihozoFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.ORCID 0000-0001-9841-1040
Suzanne PickeringDepartment of Infectious Disease, King's College London School of Medicine, Guy's Hospital, London, United Kingdom.
Talia M MotaDepartment of Microbiology, Immunology & Tropical Medicine, The George Washington University, Washington DC, United States of America.
Hua LiangDepartment of Statistics and Biostatistics, George Washington University, Washington DC, United States of America.
Gregory Q Del PreteAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.
Pramita ChatterjeeCancer and Inflammation Program, HLA Immunogenetics Section, Basic Science Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.
Guinevere Q LeeRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, United States of America.ORCID 0000-0002-9412-886X
Rasmi ThomasUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Mark A BrockmanFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.ORCID 0000-0001-6432-1426
Stuart NeilDepartment of Infectious Disease, King's College London School of Medicine, Guy's Hospital, London, United Kingdom.
Mary CarringtonCancer and Inflammation Program, HLA Immunogenetics Section, Basic Science Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, United States of America.
Bosco BwanaMbarara University of Science and Technology, Mbarara, Uganda.ORCID 0000-0002-9189-3937
David R BangsbergMbarara University of Science and Technology, Mbarara, Uganda.
Jeffrey N MartinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, United States of America.ORCID 0000-0002-9773-3256
Esper G KallasUniversity of Sao Paulo, Sao Paulo, Brazil.ORCID 0000-0003-2026-6925
Camila S DoniniUniversity of Sao Paulo, Sao Paulo, Brazil.ORCID 0000-0003-3467-2721
Natalia B CerqueiraUniversity of Sao Paulo, Sao Paulo, Brazil.
Una T O'DohertyDepartments of Medicine and Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0001-7464-8369
Beatrice H HahnDepartments of Medicine and Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-9400-9887
R Brad JonesDepartment of Microbiology, Immunology & Tropical Medicine, The George Washington University, Washington DC, United States of America.
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Douglas F NixonDepartment of Microbiology, Immunology & Tropical Medicine, The George Washington University, Washington DC, United States of America.ORCID 0000-0002-2801-1786
Richard AppsDepartment of Microbiology, Immunology & Tropical Medicine, The George Washington University, Washington DC, United States of America.ORCID 0000-0001-5140-0141
George Washington University · USSimon Fraser University · CAUniversidade de São Paulo · BRFrederick National Laboratory for Cancer Research · USGuy's Hospital · GBRagon Institute of MGH, MIT and Harvard · USUniversity of Pennsylvania · USHenry M. Jackson Foundation · USMbarara University of Science and Technology · UGPortland State University · USUniversity of California, San Francisco · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
SWG 2: Cure Research Scientific Working GroupP30AI117970 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI Italo Mocchetti · 2015 to 2026
$29.6M
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral EradicationUM1AI126617 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD, NIXON, DOUGLAS F · 2016 to 2020
$28.1M
Molecular genetics and population studies of the KIR and HLA gene complexesZIABC010792 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$7.8M
A FAST Assay to Quantify HIV ReservoirsR01AI120011 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI O'DOHERTY, UNA T, SAMBUCETTI, LIDIA C · 2015 to 2019
$3.1M
CCR NIH HHS HHSN261200800001CCIHR PJT-148621Medical Research Council G0801937NCI NIH HHS HHSN2612008000016CNCI NIH HHS HHSN261200800001ENIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI117970NIAID NIH HHS R01 AI120011NIAID NIH HHS UM1 AI126617Wellcome Trust 207442/Z/17/ZWellcome Trust WT098049AIA
6 · The paper itself

Abstract

HIV-1 can downregulate HLA-C on infected cells, using the viral protein Vpu, and the magnitude of this downregulation varies widely between primary HIV-1 variants. The selection pressures that result in viral downregulation of HLA-C in some individuals, but preservation of surface HLA-C in others are not clear. To better understand viral immune evasion targeting HLA-C, we have characterized HLA-C downregulation by a range of primary HIV-1 viruses. 128 replication competent viral isolates from 19 individuals with effective anti-retroviral therapy, show that a substantial minority of individuals harbor latent reservoir virus which strongly downregulates HLA-C. Untreated infections display no change in HLA-C downregulation during the first 6 months of infection, but variation between viral quasispecies can be detected in chronic infection. Vpu molecules cloned from plasma of 195 treatment naïve individuals in chronic infection demonstrate that downregulation of HLA-C adapts to host HLA genotype. HLA-C alleles differ in the pressure they exert for downregulation, and individuals with higher levels of HLA-C expression favor greater viral downregulation of HLA-C. Studies of primary and mutant molecules identify 5 residues in the transmembrane region of Vpu, and 4 residues in the transmembrane domain of HLA-C, which determine interactions between Vpu and HLA. The observed adaptation of Vpu-mediated downregulation to host genotype indicates that HLA-C alleles differ in likelihood of mediating a CTL response that is subverted by viral downregulation, and that preservation of HLA-C expression is favored in the absence of these responses. Finding that latent reservoir viruses can downregulate HLA-C could have implications for HIV-1 cure therapy approaches in some individuals.

Indexed as

Amino Acid SequenceDisease ReservoirsDown-RegulationGenetic VariationGenotypeHIV-1HIV InfectionsHLA-C AntigensHost-Pathogen InteractionsHuman Immunodeficiency Virus ProteinsHumansImmune EvasionViral Regulatory and Accessory ProteinsViroporin ProteinsHLA-C AntigensHuman Immunodeficiency Virus ProteinsViral Regulatory and Accessory ProteinsViroporin Proteinsvpu protein, Human immunodeficiency virus 1

Identifiers

PMID30180214
PMCPMC6138419
OpenAlexW2891753932

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.